Scholtz & Company LLC Has $2.27 Million Stake in Eli Lilly and Company (NYSE:LLY)

Scholtz & Company LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,935 shares of the company’s stock after selling 28 shares during the quarter. Eli Lilly and Company comprises 1.1% of Scholtz & Company LLC’s portfolio, making the stock its 29th biggest holding. Scholtz & Company LLC’s holdings in Eli Lilly and Company were worth $2,266,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LLY. Groupama Asset Managment increased its holdings in shares of Eli Lilly and Company by 3.8% in the fourth quarter. Groupama Asset Managment now owns 91,838 shares of the company’s stock valued at $71,068,000 after purchasing an additional 3,373 shares during the last quarter. Trexquant Investment LP boosted its holdings in shares of Eli Lilly and Company by 73.4% during the 4th quarter. Trexquant Investment LP now owns 4,421 shares of the company’s stock worth $3,413,000 after buying an additional 1,871 shares during the period. May Hill Capital LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $1,205,000. Invenio Wealth Partners LLC raised its holdings in Eli Lilly and Company by 6.5% in the 4th quarter. Invenio Wealth Partners LLC now owns 1,609 shares of the company’s stock valued at $1,242,000 after acquiring an additional 98 shares during the period. Finally, PFC Capital Group Inc. lifted its position in Eli Lilly and Company by 0.6% during the fourth quarter. PFC Capital Group Inc. now owns 6,290 shares of the company’s stock worth $4,855,000 after acquiring an additional 40 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a report on Thursday, January 16th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 2.7 %

Shares of LLY opened at $803.70 on Wednesday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The firm has a market cap of $762.04 billion, a price-to-earnings ratio of 68.63, a PEG ratio of 1.40 and a beta of 0.34. The business’s fifty day moving average is $847.53 and its 200-day moving average is $834.15.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has initiated a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.